Stener Kvinnsland
Chairman at Pluvia AS
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hilde Furberg | F | 65 |
Pluvia AS
 Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | 5 years |
| Aurora Martinez | M | - |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | - |
| Sally Bennett | M | 52 | 4 years | |
| Erlend Petter Skagseth | M | 69 |
APIM Therapeutics AS
 APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Martin Olin | M | 55 | 3 years | |
| Rune Skeie | M | 51 | 6 years | |
| Marit Otterlei | M | 61 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | 15 years |
| Gayle Mills | F | 69 | 3 years | |
| Hans Olav Minsås | M | - |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Birgitte Gangmark Villmo | F | - |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Gökhan Batur | M | 42 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | 2 years |
| Debra Stephanie Barker | M | 61 | 5 years | |
| Anders Lennart Tullgren | M | 63 | 2 years | |
| Jørgen André Nilsen | M | 58 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Randi Elisabeth Taxt | F | 59 |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | - |
| Martin Welschof | M | 63 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | 9 years |
| Konstantinos Alevizopoulos | M | 54 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Anders Haugland | M | 53 |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | - |
| Farzaad Abdi-Dezfuli | M | 61 |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Jonathan Kearsey | M | - |
APIM Therapeutics AS
APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway. | - |
| Øivind Enger | M | 68 |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | - |
| Willem van Weperen | M | - |
Pluvia AS
Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stein Holst Annexstad | M | 80 | 3 years | |
| Susan Foden | M | 71 | 8 years | |
| Richard Stuart Godfrey | M | 58 | 13 years | |
| E. Gwyn Thomas | M | - | 1 years | |
| Hani Gabra | M | - | 3 years | |
| James Barnes | M | - | 4 years | |
| Petter Nielsen | M | - | 3 years | |
| Kari Grønås | F | 59 | 3 years | |
| Murray Yule | M | - | 7 years | |
| James Lorens | M | - | 14 years | |
| Alan Barge | M | - | 1 years | |
| Tone Bjaaland | M | - | - | |
| David Wilson | M | 61 | 3 years | |
| Gro Gausdal | M | - | 8 years | |
| Pamela A. Trail | M | 68 | - | |
| Debbie Molyneux | F | - | 4 years | |
| Dominic Smethurst | M | 50 | - | |
| Grunde Eriksen | M | - | - | |
| Anthony Brown | M | - | 4 years | |
| Viki Wills | F | - | - | |
| Julia Schölermann | M | - | 4 years | |
| Grzegorz Rychlik | M | - | - | |
| François Thomas | M | 66 | - | |
| Alison Messom | M | 52 | 2 years | |
| Jon-Øyvind Eriksen | M | 60 | 7 years | |
| Nigel McCracken | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Norway | 48 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stener Kvinnsland
- Personal Network